Bridge Biotherapeutics Valuation

288330 Stock  KRW 3,455  430.00  14.21%   
At this time, the firm appears to be overvalued. Bridge Biotherapeutics shows a prevailing Real Value of W3262.35 per share. The current price of the firm is W3455.0. Our model approximates the value of Bridge Biotherapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 30.27 %, return on equity of -75.4, and Revenue of 1.92 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
3,455
Please note that Bridge Biotherapeutics' price fluctuation is very steady at this time. Calculation of the real value of Bridge Biotherapeutics is based on 3 months time horizon. Increasing Bridge Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bridge Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bridge Stock. However, Bridge Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  3455.0 Real  3262.35 Hype  3455.0 Naive  3942.14
The real value of Bridge Stock, also known as its intrinsic value, is the underlying worth of Bridge Biotherapeutics Company, which is reflected in its stock price. It is based on Bridge Biotherapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bridge Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
3,262
Real Value
3,800
Upside
Estimating the potential upside or downside of Bridge Biotherapeutics helps investors to forecast how Bridge stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bridge Biotherapeutics more accurately as focusing exclusively on Bridge Biotherapeutics' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3,1133,3453,578
Details
Hype
Prediction
LowEstimatedHigh
3,4493,4553,461
Details
Naive
Forecast
LowNext ValueHigh
3,9363,9423,948
Details

Bridge Biotherapeutics Total Value Analysis

Bridge Biotherapeutics is presently forecasted to have takeover price of 29.26 B with market capitalization of 217.07 B, debt of 53.63 M, and cash on hands of 8.2 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bridge Biotherapeutics fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
29.26 B
217.07 B
53.63 M
8.2 B

Bridge Biotherapeutics Investor Information

About 30.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Bridge Biotherapeutics had 1:1 split on the 29th of July 2024. Based on the key indicators related to Bridge Biotherapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Bridge Biotherapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.

Bridge Biotherapeutics Asset Utilization

The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Bridge suggests not a very effective usage of assets in December.

Bridge Biotherapeutics Ownership Allocation

The market capitalization of Bridge Biotherapeutics is W217.07 Billion. Bridge Biotherapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Bridge Biotherapeutics Profitability Analysis

The company reported the revenue of 1.92 B. Net Loss for the year was (26.28 B) with loss before overhead, payroll, taxes, and interest of (1.12 B).
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Bridge Biotherapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Bridge Biotherapeutics and how it compares across the competition.

About Bridge Biotherapeutics Valuation

The stock valuation mechanism determines Bridge Biotherapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Bridge Biotherapeutics. We calculate exposure to Bridge Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bridge Biotherapeutics's related companies.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.

8 Steps to conduct Bridge Biotherapeutics' Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bridge Biotherapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bridge Biotherapeutics' valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Bridge Biotherapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Bridge Biotherapeutics' revenue streams: Identify Bridge Biotherapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Bridge Biotherapeutics' industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Bridge Biotherapeutics' growth potential: Evaluate Bridge Biotherapeutics' management, business model, and growth potential.
  • Determine Bridge Biotherapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bridge Biotherapeutics' estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Complementary Tools for Bridge Stock analysis

When running Bridge Biotherapeutics' price analysis, check to measure Bridge Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridge Biotherapeutics is operating at the current time. Most of Bridge Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bridge Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bridge Biotherapeutics' price. Additionally, you may evaluate how the addition of Bridge Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes